Is McKesson Stock Outperforming the Dow?

Valued at a market cap of $80.4 billion, McKesson Corporation MCK is a leading healthcare services and information technology company. The Irving, Texas-based company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.

Companies valued at $10 billion or more are generally considered “large-cap” stocks, and McKesson fits this criterion perfectly. It provides pharmaceutical distribution, medical-surgical supply logistics, and technology-driven solutions to healthcare providers, pharmacies, and biopharma companies.

However, the prescription drug distributor is down 9.6% from its 52-week high of $653.92. Shares of MCK have gained 8% over the past three months, outperforming the 4.6% decline seen in the broader Dow Jones Industrials Average L, has underperformed MCK with a 7.1% increase over the past 52 weeks and a gain of 13.3%on a YTD basis.

Due to its strong price action over the past year, MCK has a consensus “Strong Buy” rating from the 16 analysts covering the stock. As of writing, MCK is trading below the mean price target of $677.80. 

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policyhere.